AssetMark’s Phio Pharmaceuticals PHIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$113 Hold
110
– – ﹤0.01% 3682
2026
Q2
$113 Hold
110
– – ﹤0.01% 3468
2026
Q1
$134 Hold
110
– – ﹤0.01% 3362
2025
Q4
$116 Hold
110
– – ﹤0.01% 3297
2025
Q3
$273 Hold
110
– – ﹤0.01% 3016
2025
Q2
$259 Hold
110
– – ﹤0.01% 2843
2025
Q1
$143 Buy
+110
New +$203 ﹤0.01% 2548

Other funds holding PHIO

AssetMark's PHIO Position: Q3 2026 in Review

AssetMark held its Phio Pharmaceuticals (PHIO) position steady in Q3 2026 at 110 shares worth $113. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

AssetMark first reported a position in PHIO in Q1 2025 and has held it in 7 quarters since. The position peaked at $273 in Q3 2025. 18 funds tracked by Wall St. Rank hold PHIO as of Q3 2026.

  • AssetMark held 110 shares of Phio Pharmaceuticals worth $113 as of Q3 2026.
  • AssetMark left its Phio Pharmaceuticals share count unchanged in Q3 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3682 holding.
  • AssetMark first reported a position in Phio Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • AssetMark's Phio Pharmaceuticals position peaked at $273 in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.